Evidence map›Paper›PMID 36607408›Full record

ArticleJournal of medicinal chemistry2023

Collaborative Virtual Screening Identifies a 2-Aryl-4-aminoquinazoline Series with Efficacy in an

Taisuke Tawaraishi, Atsuko Ochida, Yuichiro Akao, Sachiko Itono, Masahiro Kamaura, Thamina Akther, Mitsuyuki Shimada, Stacie Canan, Sanjoy Chowdhury, Yafeng Cao and 21 more

Open access · hybridAbstract read
In one paragraph

Article in Journal of medicinal chemistry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 7 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors at 10 institutions in 8 countries.

Taisuke TawaraishiTakeda Pharmaceutical Company Limited, 26-1 Muraoka-Higashi 2-chrome, Fujisawa, Kanagawa 251-8555, Japan.
Atsuko OchidaTakeda Pharmaceutical Company Limited, 26-1 Muraoka-Higashi 2-chrome, Fujisawa, Kanagawa 251-8555, Japan.
Yuichiro AkaoTakeda Pharmaceutical Company Limited, 26-1 Muraoka-Higashi 2-chrome, Fujisawa, Kanagawa 251-8555, Japan.
Sachiko ItonoTakeda Pharmaceutical Company Limited, 26-1 Muraoka-Higashi 2-chrome, Fujisawa, Kanagawa 251-8555, Japan.
Masahiro KamauraTakeda Pharmaceutical Company Limited, 26-1 Muraoka-Higashi 2-chrome, Fujisawa, Kanagawa 251-8555, Japan.
Thamina AktherTakeda Pharmaceutical Company Limited, 26-1 Muraoka-Higashi 2-chrome, Fujisawa, Kanagawa 251-8555, Japan.
Mitsuyuki ShimadaTakeda Pharmaceutical Company Limited, 26-1 Muraoka-Higashi 2-chrome, Fujisawa, Kanagawa 251-8555, Japan.
Stacie CananCelgene Corporation, Celgene Global Health, 10300 Campus Point Drive, San Diego, California 92121, United States.
Sanjoy ChowdhuryTCG Lifesciences, Plot No-7, Salt Lake Electronics Complex, BN Block, Sector V, Kolkata 700091, India.
Yafeng CaoWuXi AppTec Company Ltd., 666 Gaoxin Road, East Lake High-Tech Development Zone, Wuhan 430075, People's Republic of China.
Kevin CondroskiCelgene Corporation, Celgene Global Health, 10300 Campus Point Drive, San Diego, California 92121, United States.ORCID 0000-0002-5801-9332
Ola EngkvistAstraZeneca Discovery Sciences, R&D, Pepparedsleden 1, 431 50 Mölndal, Sweden.ORCID 0000-0003-4970-6461
Amanda FranciscoLondon School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, U.K.
Sunil GhoshTCG Lifesciences, Plot No-7, Salt Lake Electronics Complex, BN Block, Sector V, Kolkata 700091, India.
Rina KakiShionogi & Co., Ltd, 3-1-1, Futaba-cho, Toyonaka-shi, Osaka 561-0825, Japan.
John M KellyLondon School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, U.K.
Chiaki KimuraShionogi & Co., Ltd, 3-1-1, Futaba-cho, Toyonaka-shi, Osaka 561-0825, Japan.
Thierry KogejAstraZeneca Discovery Sciences, R&D, Pepparedsleden 1, 431 50 Mölndal, Sweden.
Kazuya NagaokaEisai Co., Ltd, 1-3, Tokodai 5-chome, Tsukuba, Ibaraki 300-2635, Japan.
Akira NaitoShionogi & Co., Ltd, 3-1-1, Futaba-cho, Toyonaka-shi, Osaka 561-0825, Japan.
Garry PairaudeauAstraZeneca, Discovery Sciences, R&D, The Darwin Building, 310 Milton Road, Milton, Cambridge CB4 0WG, U.K.
Constantin RaduInstitut Pasteur Korea, 16, Daewangpangyo-ro 712 beon-gil, Bundang-gu, Seongnam-si, Gyeonggi-do 13488, Republic of Korea.
Ieuan RobertsAstraZeneca, Discovery Sciences, R&D, The Darwin Building, 310 Milton Road, Milton, Cambridge CB4 0WG, U.K.
David ShumInstitut Pasteur Korea, 16, Daewangpangyo-ro 712 beon-gil, Bundang-gu, Seongnam-si, Gyeonggi-do 13488, Republic of Korea.
Nao-Aki WatanabeEisai Co., Ltd, 1-3, Tokodai 5-chome, Tsukuba, Ibaraki 300-2635, Japan.
Huanxu XieWuXi AppTec Company Ltd., 666 Gaoxin Road, East Lake High-Tech Development Zone, Wuhan 430075, People's Republic of China.
Shuji YonezawaShionogi & Co., Ltd, 3-1-1, Futaba-cho, Toyonaka-shi, Osaka 561-0825, Japan.
Osamu YoshidaShionogi & Co., Ltd, 3-1-1, Futaba-cho, Toyonaka-shi, Osaka 561-0825, Japan.
Ryu YoshidaShionogi & Co., Ltd, 3-1-1, Futaba-cho, Toyonaka-shi, Osaka 561-0825, Japan.
Charles MowbrayDrugs for Neglected Diseases Initiative, 15 Chemin Camille Vidart, Geneva 1202, Switzerland.ORCID 0000-0003-3538-8116
Benjamin PerryDrugs for Neglected Diseases Initiative, 15 Chemin Camille Vidart, Geneva 1202, Switzerland.ORCID 0000-0001-6715-4213
Takeda (Japan) · JPShionogi (Japan) · JPAstraZeneca (Germany) · DEAstraZeneca (Sweden) · SEDrugs for Neglected Diseases Initiative · CHEisai (Japan) · JPInstitut Pasteur Korea · KRTCG Lifesciences (India) · INUniversity of London · GBWuXi AppTec (China) · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Probing multiple proprietary pharmaceutical libraries in parallel via virtual screening allowed rapid expansion of the structure-activity relationship (SAR) around hit compounds with moderate efficacy against

Indexed as

Chagas DiseaseTrypanocidal AgentsTrypanosoma cruziHumansQuinazolinesStructure-Activity Relationship4-aminoquinazolineQuinazolinesTrypanocidal Agents

Identifiers

PMID36607408
PMCPMC9884087
OpenAlexW4313645121

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.